vitiligo

[Scientific Reports] Scientists investigated the potential biomarkers of vitiligo by evaluating the disease activity and curative effect of autologous cultured pure melanocyte transplantation on patients.

[Science Translational Medicine] Scientists performed single-cell RNA sequencing on affected and unaffected skin from patients with vitiligo, as well as healthy controls, to define the role of each cell type in coordinating autoimmunity during disease progression.

[Incyte, Inc. (Business Wire, Inc.)] Incyte. Inc, announced positive topline results from its pivotal Phase III TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream, an investigational, nonsteroidal, anti-inflammatory, JAK inhibitor, topical therapy, in adolescent and adult patients (age ≥12 years) with vitiligo.

[Cell Death & Disease] Researchers provide the first evidence that autophagy occured in melanocytes and fibroblasts from non-lesional skin of vitiligo patients, as a result of metabolic surveillance response.

[Arcutis Biotherapeutics, Inc.] Arcutis Biotherapeutics, Inc. announced enrollment of the first patient in a Phase IIa clinical trial evaluating ARQ-252 as a potential treatment for vitiligo. ARQ-252 is a potent and highly selective topical small molecule inhibitor of Janus kinase type 1.

[Nature Cancer] In a cohort of metastatic melanoma survivors with exceptional responses to immunotherapy, researchers probed memory CD8+ T-cell responses across tissues, and across several years.